<DOC>
	<DOC>NCT02152761</DOC>
	<brief_summary>The purpose of this study is to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.</brief_summary>
	<brief_title>Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery</brief_title>
	<detailed_description />
	<mesh_term>Fractures, Bone</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Hip Fractures</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Antibodies, Blocking</mesh_term>
	<criteria>Must have Xray confirmed successful hip fracture repair; must have completed surgical wound healing; ability to walk a specified distance with or without a walking aid; must weigh at least 35 kg. Must not have history of any other lower limb fractures in the past 6 months; Must not have certain cardiovascular conditions; Must not have a chronic active infection (e.g. HIV, hepatitis B or C, etc); Must not have used highdose corticosteroid medications for at least 3 months in the past year; Other protocoldefined inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>bimagrumab,</keyword>
	<keyword>BYM338,</keyword>
	<keyword>hip fracture,</keyword>
	<keyword>elderly,</keyword>
	<keyword>controlled clinical trial,</keyword>
	<keyword>randomized,</keyword>
	<keyword>muscle wasting (atrophy)</keyword>
</DOC>